{"id":3008,"date":"2023-08-31T18:52:25","date_gmt":"2023-08-31T18:52:25","guid":{"rendered":"https:\/\/cm.vastapps.dev\/tcia-collection\/acrin-6668\/"},"modified":"2023-09-13T11:55:41","modified_gmt":"2023-09-13T11:55:41","slug":"acrin-6668","status":"publish","type":"tcia_collection","link":"https:\/\/cm.vastapps.dev\/tcia-collection\/acrin-6668\/","title":{"rendered":"ACRIN-6668"},"featured_media":7582,"template":"","citation-tax":[],"cancer_types":["Non-small Cell Lung Cancer"],"citations":[2929,2930,2925],"collection_doi":"10.7937\/tcia.2019.30ilqfcl","collection_download_info":"Click the Versions tab for more info about data releases.","collection_downloads":[3127,3130,3131],"full_export":"

Summary<\/h2>

<\/span>Positron Emission Tomography Pre- and Post-treatment Assessment for Locally Advanced Non-small Cell Lung Carcinoma\u00a0<\/strong><\/p>

This was a multicenter clinical trial by the ACRIN Cooperative Group (now part of ECOG-ACRIN) and the RTOG Cooperative Group (now part of NRG) using FDG-PET imaging both pre- and post-chemoradiotherapy.\u00a0 The objective of the ACRIN 6668 multi-center clinical trial was<\/span> to determine if the PET standardized uptake value (SUV)\u00a0measurement from FDG-PET imaging shortly after treatment is a useful predictor\u00a0of long-term clinical outcome (survival) after definitive chemoradiotherapy. <\/span> <\/span>Eligible patients were those older than 18 years with AJCC-criteria clinical stage IIB\/III non-small cell lung carcinoma who were being planned for definitive concurrent chemoradiotherapy (inoperable disease). Additional information about the trial is available in the Study Protocol<\/a> and Case Report Forms<\/a>.<\/p>

Primary Aim Findings: <\/strong>Higher post-treatment tumor SUV (SUVpeak, SUVmax) is associated with worse survival in stage III NSCLC, although a clear SUV cutoff value for routine clinical use as a prognostic factor was uncertain. Later analyses found that larger pre-treatment metabolic tumor volumes (MTVs) were associated with significantly worse overall survival. Other secondary analyses found potentially predictive image texture biomarkers.<\/p>

Study Design Summary:<\/strong>\u00a0Patients received conventional concurrent platinum-based chemoradiotherapy without surgery; post-radiotherapy consolidation chemotherapy was allowed. A baseline whole-body\u00a0 FDG-PET scan was performed prior to therapy. A second post-treatment whole-body FDG-PET scan occurred approximately 14 weeks after radiotherapy (at least 4 weeks after adjuvant chemotherapy).\u00a0Pre-treatment FDG-PET scans were performed on ACRIN-qualified scanners. Post-treatment FDG-PET scans were required to be performed within 12\u201316 weeks after completion of therapy, using the same scanner as that used for the pre-treatment scans.<\/p>

Two sets of XLS spreadsheets (file set 1 and file set 2) are needed in order to obtain the entire clinical data set for this collection. The file sets are a random sample of ACRIN 6668 participants divided into 2 groups. Group 1\/file set 1: a 75% random sample; Group 2: a 25% random sample initially held for testing\/validating algorithms trained on the 75% sample.\u00a0<\/p>

Acknowledgements<\/strong><\/p>

This shared data set was provided in collaboration with the American College of Radiology Core Lab. Many thanks are due to the ACRIN 6668 trial team, and all the patients participating in the study.\u00a0\u00a0<\/span>This study was supported by the American College of Radiology Imaging network (ACRIN), which received funding from the National Cancer Institute through\u00a0UO1 CA080098,\u00a0<\/span>U01 CA21661, U01\u00a0CA32115<\/span>, U01\u00a0CA190254,\u00a0<\/span>and\u00a0R50\u00a0CA211270<\/span>\u00a0<\/span>(Muzi), under the American Recovery and Reinvestment ACT\u00a0of 2009 (ARRA) and UO1 CA079778.\u00a0Please see QIN ECOG-ACRIN Data Sharing<\/a> page for an overview and list of other ECOG-ACRIN data collections available on TCIA.<\/span><\/p>